U.S. stock night market fluctuations: Phase III trial success for myositis, Argenx rises 9.25% in after-hours tradingPrice Alert·26 minutes agoARGX-0.66%
ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3Quartr·1 hour agoARGX-0.66%
16:58 ETInvestor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firmprnewswire·10 hours agoALNY+0.67%
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord ConferenceMarket Beat·1 day ago, 06:01 PMNTRA-0.27%
TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTXMarket Beat·20 hours agoVRTX-2.07%
NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the FirmMorningStar·2 days ago, 05:30 PMALNY+0.67%
15:34 ETRegeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Bermanprnewswire·2 days ago, 02:35 PMREGN-0.31%
Natera (NTRA) Lands Kupando Trial Deal, Is The Upside Already Priced In?Simplywall·23 hours agoNTRA-0.27%
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even MoreMotley Fool·2 days ago, 03:16 PMVRTX-2.07%CRNX+0.31%
GSA Capital Partners LLP Invests $3.08 Million in Natera, Inc. $NTRAMarket Beat·22 hours agoNTRA-0.27%
7,701 Shares in Natera, Inc. $NTRA Bought by Focus Partners Advisor Solutions LLCMarket Beat·22 hours agoNTRA-0.27%UBS-0.19%
USA Financial Formulas Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGNMarket Beat·21 hours agoREGN-0.31%
Hussman Strategic Advisors Inc. Has $3.04 Million Stock Position in Amgen Inc. $AMGNMarket Beat·1 day ago, 05:49 AMAMGN-0.63%
Confluence Wealth Services Inc. Acquires 7,986 Shares of Gilead Sciences, Inc. $GILDMarket Beat·2 days ago, 03:16 AMGILD+0.16%
